A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC,
p=0.4. Risk of PCR+ at day 14, RR 0.76,
p = 0.71.
This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29,
p = 0.7.
Although the viral clearance result is not statistically significant, it is consistent with the significant 20% improved viral clearance
[10‑29%] from meta analysis of the
42 viral clearance results to date.
risk of no viral clearance, 24.0% lower, RR 0.76, p = 0.71, treatment 4 of 21 (19.0%), control 3 of 12 (25.0%), NNT 17, day 14.
|
median time to PCR-, 50.0% lower, relative time 0.50, p = 0.40, treatment 21, control 12.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Chen et al., 10 Jul 2020, Randomized Controlled Trial, Taiwan, peer-reviewed, 19 authors.
Abstract: PLOS ONE
RESEARCH ARTICLE
A multicenter, randomized, open-label,
controlled trial to evaluate the efficacy and
tolerability of hydroxychloroquine and a
retrospective study in adult patients with mild
to moderate coronavirus disease 2019
(COVID-19)
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Chen C-P, Lin Y-C, Chen T-C, Tseng T-Y,
Wong H-L, Kuo C-Y, et al. (2020) A multicenter,
randomized, open-label, controlled trial to evaluate
the efficacy and tolerability of hydroxychloroquine
and a retrospective study in adult patients with mild
to moderate coronavirus disease 2019 (COVID19). PLoS ONE 15(12): e0242763. https://doi.org/
10.1371/journal.pone.0242763
Editor: Stephen L. Atkin, Weill Cornell Medical
College Qatar, QATAR
Received: July 1, 2020
Accepted: November 9, 2020
Cheng-Pin Chen1,2☯, Yi-Chun Lin1,3☯, Tsung-Chia Chen4, Ting-Yu Tseng4, Hon-Lai Wong5,
Cheng-Yu Kuo6, Wu-Pu Lin7, Sz-Rung Huang8, Wei-Yao Wang9, Jia-Hung Liao10, ChungShin Liao11, Yuan-Pin Hung12, Tse-Hung Lin13, Tz-Yan Chang13, Chin-Fu Hsiao14, YiWen Huang ID13,15, Wei-Sheng Chung4,16,17, Chien-Yu Cheng1,18, Shu-Hsing Cheng ID1,19*,
on behalf of the Taiwan HCQ Study Group¶
1 Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan,
Taiwan, 2 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 3 Graduate Institute
of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, 4 Department of Internal Medicine, Taichung
Hospital, Ministry of Health and Welfare, Taichung, Taiwan, 5 Department of Internal Medicine, Keelung
Hospital, Ministry of Health and Welfare, Keelung City, Taiwan, 6 Department of Internal Medicine, Pingtung
Hospital, Ministry of Health and Welfare, Pingtung, Taiwan, 7 Department of Internal Medicine, Taipei
Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan, 8 Department of Internal Medicine, Miaoli
General Hospital, Ministry of Health and Welfare, Miaoli, Taiwan, 9 Department of Internal Medicine, Feng
Yuan Hospital, Ministry of Health and Welfare, Taichung, Taiwan, 10 Department of Internal Medicine,
Nantou Hospital, Ministry of Health and Welfare, Nantou, Taiwan, 11 Department of Internal Medicine, Chia
Yi Hospital, Ministry of Health and Welfare, Chiayi, Taiwan, 12 Department of Internal Medicine, Tainan
Hospital, Ministry of Health and Welfare, Tainan City, Taiwan, 13 Department of Internal Medicine, Chang
Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan, 14 Institute of Population Health Sciences,
National Health Research Institutes, Zhunan, Taiwan, 15 Institute of Medicine, Chung Shan Medical
University, Taichung, Taiwan, 16 Department of Health Service Administration, China Medical University,
Taichung, Taiwan, 17 Department of Healthcare Administration, Central Taiwan University of Science and
Technology, Taichung, Taiwan, 18 School of Public Health, National Yang-Ming University, Taipei, Taiwan,
19 School of Public Health, Taipei Medical University, Taipei, Taiwan
☯ These authors contributed equally to this work.
¶ Membership of the Taiwan HCQ Study Group is listed in the Acknowledgments.
* shcheng@mail.tygh.gov.tw
Published: December 2, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit